Histopathology reporting for personalised medicine: focus on clinical utility

被引:0
|
作者
Mason, Anna Elizabeth [1 ]
Varma, Murali [1 ]
机构
[1] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, Wales
关键词
diagnosis; neoplasms; pathology; surgical; process assessment; health care; medical oncology;
D O I
10.1136/jclinpath-2022-208185
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histopathology guidelines generally focus on standardised collection of data items to facilitate completeness and reproducibility of histopathology reporting. A data item is categorised as either core (mandatory) or non-core (recommended but not mandatory), irrespective of the clinical scenario. However, a data item that is critical for patient management in one clinical setting may have little clinical significance in another setting. A diagnosis of limited extent Gleason score 3+3=6 prostate cancer is critical in a patient being investigated for raised serum prostate-specific antigen but would be clinically irrelevant in a repeat biopsy from a patient on an active surveillance protocol. We outline an alternative approach that is focused on the clinical utility of the data items and the requirements of personalised medicine. While all core data items are required to be reported, understanding how these parameters are used to guide patient management will enable pathologists to focus time and resources on the critical aspects of an individual case. Detailed immunohistochemical workup and obtaining a second opinion would not be necessary if resolution of the differential diagnosis is of limited clinical significance. We also highlight some challenges encountered when adopting this approach and suggest some solutions that could positively impact histopathology reporting and patient care.
引用
收藏
页码:525 / 528
页数:4
相关论文
共 50 条
  • [21] Rethinking personalised medicine
    Patel, Vikram
    LANCET, 2015, 385 (9980): : 1826 - 1827
  • [22] BRONCHOALVEOLAR LAVAGE - LETS FOCUS ON CLINICAL UTILITY
    MERRILL, WW
    SMITH, GJW
    CHEST, 1992, 102 (06) : 1641 - 1641
  • [23] The promise of personalised medicine
    Matuchansky, Claude
    LANCET, 2015, 386 (9995): : 742 - 742
  • [24] The promise of personalised medicine
    Doble, Brett
    Schofield, Deborah J.
    Roscioli, Tony
    Mattick, John S.
    LANCET, 2016, 387 (10017): : 433 - 434
  • [25] The person in personalised medicine
    Doz, Francois
    Marvanne, Patrice
    Fagot-Largeault, Anne
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (05) : 1159 - 1160
  • [26] Medicine gets personalised
    Scott, A
    CHEMISTRY WORLD, 2005, 2 (07): : 32 - 36
  • [27] Personalised cancer medicine
    Jackson, Sarah E.
    Chester, John D.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 262 - 266
  • [28] Personalised medicine in the UK
    不详
    LANCET, 2018, 391 (10115): : E1 - E1
  • [29] Semiconductors in Personalised Medicine
    Toumazou, C.
    Georgiou, P.
    ELECTRONICS LETTERS, 2011, 47 (26) : S1 - S2
  • [30] Microfluidics and personalised medicine
    Davies, Mark
    Dalton, Tara
    PROCEEDINGS OF THE 4TH INTERNATIONAL CONFERENCE ON NANOCHANNELS, MICROCHANNNELS, AND MINICHANNELS, PTS A AND B, 2006, : 1221 - 1226